Key Highlights

  • Option Care Health (NASDAQ:OPCH) shares surged 22 percent after reports that McKesson and CD&R were in talks to acquire the home and alternate-site infusion provider in a deal valued around 5 billion dollars, though no transaction has been confirmed.
  • The reported approach follows a stretch of weakness for OPCH, which has traded within a 52-week range of roughly USD 18 to USD 37 and carries a market capitalization that has recently sat in the 3.4 to 4.6 billion dollar area.
  • Option Care Health (NASDAQ:OPCH) generated trailing twelve month revenue near USD 5.7 billion, with a net margin around 3.7 percent and an operating margin near 6.0 percent, figures investors can weigh independently of the reported talks.
  • The company has a recent history of large-scale M&A ambition, including a terminated 3.6 billion dollar agreement to acquire Amedisys in 2023 after a rival bidder intervened, underscoring that reported deals do not always reach completion.

Reported Five Billion Dollar Approach Remains Unconfirmed

Reports named McKesson and CD&R as discussing a possible acquisition of Option Care Health (NASDAQ:OPCH) valued around 5 billion dollars, a figure that gives investors a reference point for the scale of interest without establishing that any transaction has been agreed. The distinction matters because discussions can remain unresolved even as shares react sharply to the possibility; a jump in the stock signals a shift in expectations rather than confirmation of a deal's existence or its eventual terms. Option Care Health has direct experience with reported and even signed deals that did not reach completion: its 2023 agreement to acquire home health and hospice provider Amedisys for 3.6 billion dollars was terminated after Amedisys received a superior competing offer from Optum, with Option Care Health instead collecting a 106 million dollar termination fee. That history is a useful caution against treating any single reported figure as a settled outcome.

Surge Follows a Period of Share-Price Weakness

The reported 22 percent surge stands against a backdrop of recent weakness: Option Care Health shares have traded as low as roughly 18 dollars over the past year, well below a 52-week high near 37 dollars, and the stock has underperformed over both the past year and the past six months by several measures. That contrast places the reported jump alongside a weaker longer-term trend rather than confirmation that sentiment has durably turned. Option Care Health (NASDAQ:OPCH) has continued smaller tuck-in acquisitions in recent years, including an infusion provider purchase that closed in January, while management has described M&A as a continuing priority even after the Amedisys outcome. The current reports, if accurate, would represent a far larger scale of corporate action than those recent, smaller deals.

Revenue Scale and Margins Provide Independent Context

Option Care Health's trailing twelve month revenue sits near 5.7 billion dollars, with gross margin around 19 percent, operating margin near 6.0 percent and net margin around 3.7 percent, figures that describe a business generating meaningful scale with comparatively thin profitability common to infusion and home health services. Return on equity has been reported near the mid-teens percentage range in recent periods, while the company has used free cash flow for continued share buybacks, including more than 167 million dollars repurchased in the first half of 2026 alone. These figures can help investors assess the company independently of the acquisition reports, but they do not specify what McKesson or CD&R might ultimately agree to pay, or whether the reported discussions will produce a binding agreement at all.

Where Things Stand

The reported 22 percent surge in Option Care Health shares followed news that McKesson and CD&R were in talks for a roughly 5 billion dollar acquisition, but no completed transaction or confirmed terms have been reported. The company's own history, including its terminated Amedisys agreement, shows that even advanced discussions can fail to close. The balance of evidence favors treating this as a developing possibility rather than a settled outcome, with the stock's reaction reflecting a shift in expectations rather than proof of a deal. The next milestone to watch is confirmation of formal terms or a definitive agreement.